Advancing targeted therapy for colorectal cancer: harnessing ligand-directed enzyme prodrug therapy for highly specific interventions
Colorectal cancer (CRC) is a significant global health burden, ranking as the third most frequently diagnosed cancer and a leading cause of cancer-related mortality. Current therapeutic modalities face challenges in advanced stages, including drug resistance, toxicity, and off-target effects. Ligand...
Saved in:
| Main Authors: | Hend Al-Jaber, Kabir H. Biswas, Layla Al-Mansoori |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1570712/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prodrug–carboxypeptidase G2 therapy: certain concerns on carboxypeptidase G2
by: Tinghe Yu, et al.
Published: (2025-06-01) -
Current Trends in Clinical Trials of Prodrugs
by: Diogo Boreski, et al.
Published: (2025-02-01) -
Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy
by: Jinzhe Liang, et al.
Published: (2024-09-01) -
Hyaluronic acid-tailored prodrug nanoplatforms for efficiently overcoming colorectal cancer chemoresistance and recurrence by synergistic inhibition of cancer cell stemness
by: Xirui Duan, et al.
Published: (2025-07-01) -
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)